LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.34 $ -0.06 (-4.26 %)    

Tuesday, 14-Oct-2025 17:59:56 EDT
QQQ $ 598.25 $ -4.01 (-0.67 %)
DIA $ 462.74 $ 2.03 (0.44 %)
SPY $ 662.28 $ -0.81 (-0.12 %)
TLT $ 90.62 $ 0.29 (0.32 %)
GLD $ 382.97 $ 2.70 (0.71 %)
$ 1.35
$ 1.45
$ 1.33 x 250
$ 1.35 x 1,050
$ 1.25 - $ 1.50
$ 1.12 - $ 33.66
643,912
na
31.46M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION